Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug KK2260 enters first human tests

NCT ID NCT06248411

Recruiting now Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Feb 22, 2026 · Last updated Jun 22, 2026 · Updated 16 times

Summary

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. About 189 participants will be enrolled to evaluate safety, side effects, and early signs of tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aichi Cancer Center Hospital

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Hiroshima University Hospital

    RECRUITING

    Hiroshima, Hiroshima, 734-8551, Japan

  • Kanagawa Cancer Center

    RECRUITING

    Yokohama, Kanagawa, 241-8515, Japan

  • Kobe University Hospital

    RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Kumamoto University Hospital

    RECRUITING

    Kumamoto, Kumamoto, 860-8556, Japan

  • Kyushu Cancer Center

    RECRUITING

    Fukuoka, 811-1347, Japan

  • National Cancer Center Hospital

    RECRUITING

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • Osaka International Cancer Institute

    RECRUITING

    Osaka, 540-0008, Japan

  • Saitama Cancer Center

    RECRUITING

    Shinden, Saitama, 362-0806, Japan

  • Shikoku Cancer Center

    RECRUITING

    Matsuyama, Ehime, 791-0280, Japan

  • Shizuoka Cancer Center

    RECRUITING

    Nagaizumi-cho, Shizuoka, 411-8777, Japan

  • The Cancer Institute Hospital of JFCR

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • Tohoku University Hospital

    RECRUITING

    Sendai, Miyagi, 980-8574, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

KK2260 (an experimental drug given intravenously)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced solid tumors, including esophageal and head and neck cancers.

What could go wrong

This is a very early, first-in-human study with a small number of participants. The drug may not work or could cause unexpected side effects. It will take years before any potential treatment is available.

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma head and neck squamous cell carcinoma metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS ADVANCED OR METASTATIC SOLID TUMORS